X

Trial Profile

Study of Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cell(C-CAR011) Treatment in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19 chimeric antigen receptor T cell therapy AbelZeta Pharma (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Cellular Biomedicine Group

Most Recent Events

08 Aug 2017 According to a Cellular Biomedicine Group media release, top-line data from the study is expected by year-end.
19 May 2017 New trial record
15 May 2017 According to a Cellular Biomedicine meida release, the company anticipates topline data in the fourth quarter of 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com